Susquehanna International Group
LCTX icon

Susquehanna International Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Susquehanna International Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.4K Sell
21,800
-31,300
-59% -$52.8K ﹤0.01% 12731
2025
Q4 		$88.7K Buy
53,100
+24,000
+82% +$41.5K ﹤0.01% 11517
2025
Q3 		$49.2K Buy
+29,100
New +$34.4K ﹤0.01% 11865
2022
Q3 		– Sell
-10,700
Closed -$17K – 13714
2022
Q2 		$17K Sell
10,700
-43,400
-80% -$57.2K ﹤0.01% 12402
2022
Q1 		$83K Sell
54,100
-24,000
-31% -$37.2K ﹤0.01% 12026
2021
Q4 		$191K Sell
78,100
-115,100
-60% -$269K ﹤0.01% 11497
2021
Q3 		$487K Buy
193,200
+100,200
+108% +$257K ﹤0.01% 9457
2021
Q2 		$265K Sell
93,000
-25,900
-22% -$67K ﹤0.01% 11040
2021
Q1 		$279K Buy
118,900
+92,400
+349% +$222K ﹤0.01% 10759
2020
Q4 		$47K Buy
+26,500
New +$37.1K ﹤0.01% 10764
2019
Q4 		– Sell
-12,700
Closed -$12K – 10215
2019
Q3 		$12K Sell
12,700
-5,100
-29% -$5.28K ﹤0.01% 10002
2019
Q2 		$20K Sell
17,800
-9,100
-34% -$10.5K ﹤0.01% 10005
2019
Q1 		$35K Buy
+26,900
New +$33.5K ﹤0.01% 8533
2018
Q3 		– Sell
-20,917
Closed -$38K – 9780
2018
Q2 		$38K Buy
20,917
+3,200
+18% +$6.44K ﹤0.01% 9330
2018
Q1 		$42K Buy
+17,717
New +$41.5K ﹤0.01% 9007
2017
Q4 		– Sell
-29,032
Closed -$72K – 9610
2017
Q3 		$72K Buy
+29,032
New +$72K ﹤0.01% 8455
2016
Q3 		– Sell
-11,773
Closed -$27K – 8747
2016
Q2 		$27K Sell
11,773
-1,143
-9% -$2.8K ﹤0.01% 8341
2016
Q1 		$32K Buy
+12,916
New +$28.8K ﹤0.01% 8754
2015
Q4 		– Sell
-50,923
Closed -$123K – 9706
2015
Q3 		$123K Sell
50,923
-22,798
-31% -$59K ﹤0.01% 9036
2015
Q2 		$216K Buy
73,721
+22,302
+43% +$86.5K ﹤0.01% 9163
2015
Q1 		$206K Buy
51,419
+22,922
+80% +$79.3K ﹤0.01% 8599
2014
Q4 		$86K Sell
28,497
-70,748
-71% -$191K ﹤0.01% 9233
2014
Q3 		$252K Buy
99,245
+58,729
+145% +$141K ﹤0.01% 8292
2014
Q2 		$100K Buy
40,516
+6,319
+18% +$14.3K ﹤0.01% 9427
2014
Q1 		$91K Sell
34,197
-48,817
-59% -$144K ﹤0.01% 8586
2013
Q4 		$241K Sell
83,014
-39,400
-32% -$119K ﹤0.01% 7953
2013
Q3 		$375K Sell
122,414
-13,630
-10% -$43.1K ﹤0.01% 6879
2013
Q2 		$435K Buy
+136,044
New +$436K ﹤0.01% 6251

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's LCTX Position: Q1 2026 in Review

Susquehanna International Group increased its Lineage Cell Therapeutics (LCTX) stake by 85% in Q1 2026, buying an estimated $1.01M and bringing the position to 1,304,685 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #6121.

Susquehanna International Group first reported a position in LCTX in Q2 2013 and has held it in 39 quarters since. The position peaked at $2.35M in Q1 2021. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Susquehanna International Group held 1,304,685 shares of Lineage Cell Therapeutics worth $2.06M as of Q1 2026.
  • Susquehanna International Group bought 598,270 Lineage Cell Therapeutics shares in Q1 2026, an estimated $1.01M.
  • Lineage Cell Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6121 holding.
  • Susquehanna International Group first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 39 quarters since.
  • Susquehanna International Group's Lineage Cell Therapeutics position peaked at $2.35M in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.